You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCR-RET

Showing 1 - 25 of 281
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Worldwide

Active, not recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +39 more
  • pralsetinib (BLU-667)
  • Phoenix, Arizona
  • +65 more
Nov 10, 2022

NSCLC, Medullary Thyroid Cancer, Colon Cancer Trial in Worldwide (LOXO-292)

Recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Scottsdale, Arizona
  • +84 more
Oct 10, 2022

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Nonsmall Cell Lung Cancer Trial in Shanghai (HS-10365 capsules)

Recruiting
  • Nonsmall Cell Lung Cancer
  • HS-10365 capsules
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Nov 22, 2023

RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer Trial in Chang chun

Not yet recruiting
  • RET-altered Non Small Cell Lung Cancer
  • +3 more
  • Chang chun, Jilin, China
    Jinlin Province Cancer Hosipital
Dec 21, 2022

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors Trial in Canada (Olaparib, Dasatinib, Nivolumab plus Ipilimumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • +2 more
  • Edmonton, Alberta, Canada
  • +9 more
Jan 9, 2023

CML, Chronic Phase, CML, Accelerated Phase Trial in Wuhan (HS-10382(Part 1: Dose escalation), HS-10382(Part 2: Dose expansion))

Recruiting
  • CML, Chronic Phase
  • CML, Accelerated Phase
  • HS-10382(Part 1: Dose escalation)
  • HS-10382(Part 2: Dose expansion)
  • Wuhan, Hubei, China
    Union Hospital affiliated to Tongji Medical College of Huazhong
Jan 12, 2023

NSCLC Trial in Shanghai (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Sep 4, 2023

IBD, Ulcerative Colitis, Crohn Disease Trial in Stanford (Vitamin D)

Recruiting
  • Inflammatory Bowel Diseases
  • +2 more
  • Vitamin D
  • Stanford, California
    Stanford University School of Medicine
Oct 24, 2022

Advanced Solid Tumor Trial in Los Angeles (EP0031)

Recruiting
  • Advanced Solid Tumor
  • Los Angeles, California
  • +3 more
Dec 1, 2022

Refractory Solid Tumors Trial in Seoul (sunitinib)

Completed
  • Refractory Solid Tumors
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 13, 2022

Solid Tumor, Medullary Thyroid Cancer Trial in China (Selpercatinib)

Active, not recruiting
Has Results
  • Solid Tumor
  • Medullary Thyroid Cancer
  • Guangzhou, Guangdong, China
  • +12 more
May 9, 2022

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in United States (Bosutinib, Dasatinib, Laboratory Biomarker

Active, not recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Anchorage, Alaska
  • +540 more
Dec 14, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +37 more
  • Birmingham, Alabama
  • +171 more
Aug 24, 2022

MDD Trial in Ames (Resistance Exercise Training)

Active, not recruiting
  • Major Depressive Disorder
  • Resistance Exercise Training
  • Ames, Iowa
    Iowa State University
Jan 12, 2023

NSCLC, Medullary Thyroid Cancer, Solid Tumor Trial in Shanghai, Tianjin (SY-5007)

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Shanghai, Shanghai, China
  • +1 more
Mar 17, 2022

Stroke Trial (Power-focused resistance training)

Not yet recruiting
  • Stroke
  • Power-focused resistance training
  • (no location specified)
Apr 18, 2023

Biochemical Recurrence of Malignant Tumor of Prostate, Prostate Cancer, BCR Prostate Carcinoma Trial in China (68Ga-PSMA-11,

Not yet recruiting
  • Biochemical Recurrence of Malignant Neoplasm of Prostate
  • +2 more
  • Changsha, China
  • +5 more
Apr 26, 2023

NSCLC, Thyroid Tumors Trial (LOXO-260)

Temporarily not available
  • Carcinoma, Non-Small-Cell Lung
  • Thyroid Neoplasms
  • (no location specified)
Sep 20, 2022

Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer Trial in Singapore (Oral lenvatinib + Intravenous (IV)

Not yet recruiting
  • Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
  • Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 13, 2022

RET-altered Solid Tumors Trial in Shanghai (APS03118)

Recruiting
  • RET-altered Solid Tumors
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Dec 8, 2022

Urologic Cancer, Biochemical Recurrence of Malignant Tumor of Prostate Trial in Freiburg (Pembrolizumab Injection [Keytruda],

Recruiting
  • Urologic Cancer
  • Biochemical Recurrence of Malignant Neoplasm of Prostate
  • Pembrolizumab Injection [Keytruda]
  • Salvage Radiation Therapy (SRT)
  • Freiburg, Baden-Württemberg, Germany
    Clinic of Urology, Medical Center - University of Freiburg
Nov 7, 2022

Mature B Cell Tumors Trial in Tianjin (SHR1459)

Active, not recruiting
  • Mature B Cell Neoplasms
  • Tianjin, Tianjin, China
    Blood disease hospital of Chinese Academy of Medical Sciences
Nov 10, 2022

Prostate Cancer Trial in Lexington (ArtemiCoffee)

Not yet recruiting
  • Prostate Cancer
  • Lexington, Kentucky
    University of Kentucky
Jul 25, 2022